reports
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Glo...
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City. Rick Barry, President and Chief Executive ...
Cassava Reports Q2 2025 Financials Results and Provides Business Updat...
Cassava Reports Q2 2025 Financials Results and Provides Business Update Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2...
Abbvie Inc: 1 director
A director at Abbvie Inc sold 13,295 shares at 198.512USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointme...
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufil...
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders...
Johnson & Johnson: 1 director
A director at Johnson & Johnson sold 19,137 shares at 163.549USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 July 2025 in which we reassessed the appropriateness of the ratings in the context of the re...
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance ...
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that the Company presented a poster at the (TSC 2025) held June 26-28, 202...
- Pierre François Merveille
- Pierre François Merveille
Cassava Reports Q1 2025 Financials Results, Provides Business Update
Cassava Reports Q1 2025 Financials Results, Provides Business Update License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2025, an...
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program...
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Borde...
- Research Team ACF
ACF Thematic Oncology Lung Cancer Cough LCC 25042025
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
- Pierre François Merveille
Teva : On the road to investment grade
Teva successfully delivered the 1st phase of its ‘Pivot To Growth’ strategy with a return to revenue growth in 2023 and 2024 (+3% and +9% on constant FX respectively, excluding a $ 500m payment from Sanofi in Q4 2023). The company will now enter the 2nd phase of its strategy (‘accelerate growth’) with a sustained momentum for its AUSTEDO/AJOVY and a good a pipeline of biosimilar and innovative drugs (Olanzapine LAI in 2026, DARI in 2027). These developments should more than compensate for pricin...
- Pierre François Merveille
Teva : On the road to investment grade
Teva successfully delivered the 1st phase of its ‘Pivot To Growth’ strategy with a return to revenue growth in 2023 and 2024 (+3% and +9% on constant FX respectively, excluding a $ 500m payment from Sanofi in Q4 2023). The company will now enter the 2nd phase of its strategy (‘accelerate growth’) with a sustained momentum for its AUSTEDO/AJOVY and a good a pipeline of biosimilar and innovative drugs (Olanzapine LAI in 2026, DARI in 2027). These developments should more than compensate for pricin...
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec,...
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Comp...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Johnson & Johnson and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 April 2025 in which we reassessed the appropriateness of the ratings in the context of ...
Moody's Ratings says J&J's talc overhang remains after court ruling, b...
Moody's Ratings (Moody's) said that Johnson & Johnson's ("J&J") talc overhang remains after its latest talc subsidiary bankruptcy attempt was denied in courts, but its strong business profile and financial flexibility mitigate ongoing litigation pressures. There is no change at this time to J&J's ra...
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety profileCassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.